[go: up one dir, main page]

HUS2200028I1 - Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések - Google Patents

Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések

Info

Publication number
HUS2200028I1
HUS2200028I1 HUS2200028C HUS2200028C HUS2200028I1 HU S2200028 I1 HUS2200028 I1 HU S2200028I1 HU S2200028 C HUS2200028 C HU S2200028C HU S2200028 C HUS2200028 C HU S2200028C HU S2200028 I1 HUS2200028 I1 HU S2200028I1
Authority
HU
Hungary
Prior art keywords
stabilize
formulations
immunogenic compositions
inhibit precipitation
precipitation
Prior art date
Application number
HUS2200028C
Other languages
English (en)
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38441477&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUS2200028(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of HUS2200028I1 publication Critical patent/HUS2200028I1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUS2200028C 2006-04-26 2022-06-09 Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések HUS2200028I1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79526106P 2006-04-26 2006-04-26
EP13185292.3A EP2676679B2 (en) 2006-04-26 2007-04-19 Use of formulations to stabilize and inhibit precipitation of immunogenic compositions

Publications (1)

Publication Number Publication Date
HUS2200028I1 true HUS2200028I1 (hu) 2022-07-28

Family

ID=38441477

Family Applications (5)

Application Number Title Priority Date Filing Date
HUE13186454A HUE055682T2 (hu) 2006-04-26 2007-04-19 Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések
HUE13186453A HUE058394T2 (hu) 2006-04-26 2007-04-19 Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések
HUE13185292A HUE042923T2 (hu) 2006-04-26 2007-04-19 Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések
HUE07760907A HUE028137T2 (hu) 2006-04-26 2007-04-19 Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések
HUS2200028C HUS2200028I1 (hu) 2006-04-26 2022-06-09 Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések

Family Applications Before (4)

Application Number Title Priority Date Filing Date
HUE13186454A HUE055682T2 (hu) 2006-04-26 2007-04-19 Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések
HUE13186453A HUE058394T2 (hu) 2006-04-26 2007-04-19 Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések
HUE13185292A HUE042923T2 (hu) 2006-04-26 2007-04-19 Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések
HUE07760907A HUE028137T2 (hu) 2006-04-26 2007-04-19 Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések

Country Status (31)

Country Link
US (3) US7935787B2 (hu)
EP (5) EP2679245B1 (hu)
JP (7) JP5612305B2 (hu)
KR (9) KR101514913B1 (hu)
CN (4) CN101500612B (hu)
AR (2) AR060665A1 (hu)
AU (1) AU2007243019B2 (hu)
BR (2) BR122020000285B1 (hu)
CA (3) CA2873346C (hu)
CL (1) CL2007001185A1 (hu)
CR (1) CR10405A (hu)
CY (2) CY1116966T1 (hu)
DK (4) DK2679245T3 (hu)
EA (2) EA023470B1 (hu)
ES (4) ES2557504T3 (hu)
FI (2) FI2676679T4 (hu)
FR (1) FR22C1027I2 (hu)
HR (3) HRP20190198T4 (hu)
HU (5) HUE055682T2 (hu)
IL (3) IL194753A (hu)
LT (2) LT2676679T (hu)
LU (1) LUC00267I2 (hu)
MX (3) MX2008013572A (hu)
PL (4) PL2676679T5 (hu)
PT (4) PT2010219E (hu)
RU (1) RU2482878C2 (hu)
SI (4) SI2679244T1 (hu)
TR (1) TR201902402T4 (hu)
TW (1) TW200806315A (hu)
WO (1) WO2007127665A2 (hu)
ZA (1) ZA200809167B (hu)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9910089A (pt) 1998-05-01 2004-06-08 Chiron Corp Composições e antìgenos de neisseria meningitidis
ES2563650T3 (es) 1999-05-19 2016-03-15 Glaxosmithkline Biologicals Sa Composiciones de combinaciones de Neisseria
EP2275553B1 (en) 1999-10-29 2015-05-13 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigenic peptides
ES2299476T3 (es) 2000-02-28 2008-06-01 Novartis Vaccines And Diagnostics S.R.L. Expresion hibrida de proteinas de neisseria.
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CL2008003808A1 (es) * 2007-12-21 2011-03-11 Glaxosmithkline Biologicals Sa Componente de vacuna contra la malaria que comprende una particula inmunogena rts,s y/o una particula que se deriva de la proteina cs de una o mas cepas de p. vivax y el antigeno s de la hepatitis b o una particula inmunogena que comprende rts, csv-s y opcionalmente el antigeno s sin fusionar y un agente estabilizante ; y vacuna.
CA2716212A1 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
NZ595234A (en) 2009-03-24 2013-12-20 Novartis Ag Adjuvanting meningococcal factor h binding protein
CN102438649A (zh) * 2009-03-24 2012-05-02 诺华有限公司 脑膜炎球菌h因子结合蛋白和肺炎球菌结合糖的组合物
ES2552153T3 (es) 2009-04-30 2015-11-26 Coley Pharmaceutical Group, Inc. Vacuna neumocócica y usos de la misma
PL3170508T3 (pl) * 2010-06-04 2020-04-30 Wyeth Llc Preparaty szczepionek
US8802603B2 (en) 2010-06-17 2014-08-12 Becton, Dickinson And Company Medical components having coated surfaces exhibiting low friction and low reactivity
CA2803239A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
ES2994878T3 (en) * 2010-08-23 2025-02-03 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
FR2966044B1 (fr) * 2010-10-18 2012-11-02 Sanofi Pasteur Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium
LT2637690T (lt) 2010-11-11 2016-10-25 Abbvie Biotechnology Ltd Didelės koncentracijos anti-tnfalfa antikūno skystos kompozicijos
AR084158A1 (es) * 2010-12-10 2013-04-24 Merck Sharp & Dohme Formulaciones que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas
JP2015505309A (ja) 2011-12-29 2015-02-19 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ
BR122016004924A2 (pt) 2012-03-09 2019-07-30 Pfizer Inc. Polipeptídeo isolado e composições imunogênicas compreendendo os mesmos
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
NZ630133A (en) 2012-06-14 2016-10-28 Novartis Ag Vaccines for serogroup x meningococcus
CN108718410B (zh) 2012-06-26 2022-05-24 Lg 电子株式会社 视频编码方法、视频解码方法和使用其的装置
JOP20200175A1 (ar) * 2012-07-03 2017-06-16 Novartis Ag حقنة
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
PL3060256T3 (pl) * 2013-10-25 2019-10-31 Bayer Pharma AG Nowa stabilna formulacja
CN110859957B (zh) * 2014-01-21 2024-04-12 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2016276269B2 (en) * 2015-06-08 2021-01-28 Serum Institute Of India Private Ltd. Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof
KR20210027523A (ko) * 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
US10702606B2 (en) * 2015-12-10 2020-07-07 Menicon Co., Ltd. Peptide composition
EP4309670A3 (en) 2016-09-02 2024-07-17 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN110366428B (zh) 2016-12-30 2024-05-17 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
CN106620681A (zh) * 2017-01-12 2017-05-10 南京佰泰克生物技术有限公司 一种细胞裂解液、试剂盒及在制备肿瘤全细胞抗原负载dc肿瘤疫苗中的应用
US20200222550A1 (en) 2017-01-31 2020-07-16 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN110225764A (zh) 2017-01-31 2019-09-10 默沙东公司 制备多糖-蛋白缀合物的方法
WO2018156467A1 (en) * 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Methods for improving filterability of polysaccharide-protein conjugate reactions
AU2018225099B2 (en) 2017-02-24 2024-08-22 Merck Sharp & Dohme Llc Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates
DK3585803T3 (da) * 2017-02-24 2025-12-15 Merck Sharp & Dohme Llc Formuleringer af pneumokokkal konjugatvaccine
CA3074711A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US11395849B2 (en) 2017-09-07 2022-07-26 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
JP2021501144A (ja) * 2017-10-25 2021-01-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． アジュバントワクチン
SG11202005255PA (en) 2017-12-06 2020-07-29 Merck Sharp & Dohme Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US12144855B2 (en) 2018-04-30 2024-11-19 Merck Sharp & Dohme Llc Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres
US11896656B2 (en) 2018-04-30 2024-02-13 Merck Sharp & Dohme Llc Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
US20210252125A1 (en) 2018-04-30 2021-08-19 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
US20220047703A1 (en) * 2018-09-24 2022-02-17 BioVaxys Inc. Bihaptenized autologous vaccines and uses thereof
JOP20210148A1 (ar) 2018-12-19 2023-01-30 Merck Sharp & Dohme تركيبات تشتمل على متقارنات بولي سكاريد-بروتين للمكورات العقدية الرئوية وطرق استخدامها
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP2023512446A (ja) * 2020-01-13 2023-03-27 アプティーボ リサーチ アンド デベロップメント エルエルシー 治療的タンパク質の薬物送達システム構成要素への吸着を防ぐ方法および組成物
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
WO2022180648A1 (en) 2021-02-26 2022-09-01 Biological E Limited Activated-quenched polysaccharide and improved methods for quantification of polysaccharide in a vaccine composition
AU2022281543A1 (en) * 2021-05-28 2023-11-23 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1189340A (en) * 1967-09-13 1970-04-22 American Cyanamid Co Antigen-Adjuvant Composition
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
EP0467173B1 (en) * 1990-07-19 1995-11-08 Nardino Righi Disposable safety syringe
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
JPH07507854A (ja) 1991-12-23 1995-08-31 ツォッヒェ，ミヒャエル 油除去装置を備えたエンジン
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
DE69327599T2 (de) 1992-06-25 2000-08-10 Smithkline Beecham Biolog Adjuvantien enthaltende Impfstoffzusammensetzung
ES2231770T3 (es) 1993-03-05 2005-05-16 Wyeth Holdings Corporation Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP3696267B2 (ja) 1994-02-28 2005-09-14 天野エンザイム株式会社 生理活性蛋白質の安定化方法
DE4407489A1 (de) * 1994-03-07 1995-09-14 Bayer Ag Vakzine zur Prävention von Respirations- und Reproduktionserkrankungen des Schweines
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5846547A (en) * 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5932223A (en) 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
RU2098109C1 (ru) 1996-09-26 1997-12-10 Александр Григорьевич Чучалин Противоаллергическое, противовоспалительное средство, способ его получения, лечебное и косметическое средства с его использованием
US6403098B1 (en) 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
JP4078406B2 (ja) 1997-01-22 2008-04-23 有限会社コーキ・エンジニアリング 注射器のシリンダの製造方法
CN1259051A (zh) * 1997-04-08 2000-07-05 麦克公司 稳定化后的人乳头瘤病毒制剂
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
CA2264970A1 (en) * 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
ATE378066T1 (de) 1998-09-30 2007-11-15 Wyeth Corp Mutiertes cholera holotoxin als hilfsmittel
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
DE122009000054I1 (de) 1999-03-19 2009-12-31 Glaxosmithkline Biolog Sa Impfstoff gegen bakterielle antigene
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
JP4948731B2 (ja) * 1999-12-02 2012-06-06 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 凍結乾燥の際に生物学的分子を安定化するための組成物および方法
DE10012370A1 (de) * 2000-03-14 2001-09-27 Chiron Behring Gmbh & Co Adjuvans für Vakzinen
RU2293573C2 (ru) 2000-06-08 2007-02-20 Интерселл Аг Иммуностимулирующие олигодезоксинуклеотиды
CN1449293B (zh) * 2000-06-29 2012-08-22 史密丝克莱恩比彻姆生物有限公司 多价疫苗组合物
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
KR100385711B1 (ko) * 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
WO2002004497A2 (en) * 2000-07-10 2002-01-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multiple antigenic peptides immunogenic against streptococcus pneumoniae
GB0025414D0 (en) * 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
WO2002074325A1 (en) * 2001-03-19 2002-09-26 Iomai Corporation Patch for transcutaneous immunization
ATE451386T1 (de) 2001-06-07 2009-12-15 Wyeth Corp Mutantenformen von cholera holotoxin als adjuvans
JP2005508143A (ja) 2001-06-07 2005-03-31 ワイス・ホールデイングス・コーポレーシヨン アジュバントとしてのコレラホロトキシンの突然変異形
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
CA2452720C (en) 2001-07-26 2012-04-17 Chiron S.R.L. Vaccines comprising aluminium adjuvants and histidine
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
NZ532896A (en) * 2001-11-08 2007-08-31 Pdl Biopharma Inc Stable liquid pharmaceutical formulation of IGG antibodies including daclizumab and fontolizumab
EP1590459A2 (en) 2003-01-15 2005-11-02 Wyeth Holdings Corporation Methods for increasing neisseria protein expression and compositions thereof
ES2383175T3 (es) * 2003-01-30 2012-06-18 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
JP4728948B2 (ja) * 2003-02-10 2011-07-20 エラン ファーマシューティカルズ，インコーポレイテッド 免疫グロブリン製剤およびその調製の方法
WO2004083251A2 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
AU2004233012A1 (en) * 2003-04-16 2004-11-04 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
WO2005000244A2 (en) * 2003-06-25 2005-01-06 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis
UA67144A (en) 2003-07-29 2004-06-15 Inst Exprm & Clinical Veterina Method for production of inactivated vaccine against salmonellosis and escherichiosis of animals
CA2535043A1 (en) 2003-08-06 2005-04-28 Ellen Jessouroun Process for preparing polysaccharide-protein conjugate vaccines
DE10348550A1 (de) * 2003-10-20 2005-06-16 Hexal Biotech Forschungsgmbh Stabile wässrige G-CSF-haltige Zusammensetzungen
RU37462U1 (ru) 2004-01-16 2004-04-27 Бычкова Ольга Владимировна Пробирка
CA2586058A1 (en) * 2004-11-01 2006-05-11 Dennis L. Kasper Modified streptococcal polysaccharides and uses thereof
CN101111264A (zh) * 2005-01-28 2008-01-23 惠氏公司 稳定化的液体多肽制剂
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
DK1868645T3 (da) * 2005-04-08 2012-04-10 Wyeth Llc Multivalent pneumokok-sakkarid-protein-konjugat-sammensætning
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
WO2007127668A2 (en) 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
JP5689687B2 (ja) 2008-03-05 2015-03-25 サノフィ・パスツールＳａｎｏｆｉｐａｓｔｅｕｒ アジュバント含有ワクチン組成物の安定化方法

Also Published As

Publication number Publication date
CN103768615A (zh) 2014-05-07
IL239788A0 (en) 2015-08-31
IL194753A0 (en) 2009-08-03
HUE055682T2 (hu) 2021-12-28
RU2482878C2 (ru) 2013-05-27
PT2676679T (pt) 2019-03-01
KR101514913B1 (ko) 2015-04-23
EP3517129A1 (en) 2019-07-31
ES2712956T5 (en) 2025-02-10
CN104857524A (zh) 2015-08-26
JP6321094B2 (ja) 2018-05-09
LTPA2022509I1 (hu) 2022-06-27
EP2679245A2 (en) 2014-01-01
KR20160049063A (ko) 2016-05-04
CA2873346C (en) 2017-09-05
EP2679244A3 (en) 2014-01-15
US7935787B2 (en) 2011-05-03
HK1223569A1 (zh) 2017-08-04
EP2676679A2 (en) 2013-12-25
AR060665A1 (es) 2008-07-02
IL239978B (en) 2019-06-30
LT2676679T (lt) 2019-03-12
SI2679244T1 (sl) 2022-05-31
CA2803111C (en) 2015-06-16
FI2676679T4 (fi) 2024-10-31
ZA200809167B (en) 2009-06-24
HRP20190198T1 (hr) 2019-04-05
EP2676679A3 (en) 2014-01-01
PT2679245T (pt) 2021-09-02
HUE058394T2 (hu) 2022-08-28
EP2679244A2 (en) 2014-01-01
CN103768615B (zh) 2016-06-01
EA017436B1 (ru) 2012-12-28
JP2018123145A (ja) 2018-08-09
US20130034580A1 (en) 2013-02-07
DK2679244T3 (da) 2022-04-11
HRP20151203T1 (hr) 2015-12-04
ES2712956T3 (es) 2019-05-16
KR20220061256A (ko) 2022-05-12
MX2018012171A (es) 2021-12-08
HRP20190198T4 (hr) 2024-10-25
CY1116966T1 (el) 2017-04-05
PT2010219E (pt) 2016-01-29
KR102093269B1 (ko) 2020-04-23
KR20090017537A (ko) 2009-02-18
PT2679244T (pt) 2022-04-19
PL2010219T3 (pl) 2016-03-31
JP2016222701A (ja) 2016-12-28
DK2676679T3 (en) 2019-03-04
MX2008013572A (es) 2009-03-06
CA2650056C (en) 2013-07-16
DK2676679T4 (da) 2024-09-16
JP5612305B2 (ja) 2014-10-22
KR20180130004A (ko) 2018-12-05
AU2007243019B2 (en) 2012-06-21
RU2008141680A (ru) 2010-06-10
JP2021176910A (ja) 2021-11-11
BRPI0710918B1 (pt) 2021-02-02
CA2803111A1 (en) 2007-11-08
CN104857524B (zh) 2018-08-28
FIC20220022I1 (fi) 2022-06-13
US20070253984A1 (en) 2007-11-01
CA2650056A1 (en) 2007-11-08
CR10405A (es) 2009-02-26
DK2679245T3 (da) 2021-09-06
KR20170122857A (ko) 2017-11-06
EA023470B1 (ru) 2016-06-30
SI2676679T2 (sl) 2025-05-30
KR20200032268A (ko) 2020-03-25
AR110731A2 (es) 2019-04-24
SI2676679T1 (sl) 2019-03-29
HUE042923T2 (hu) 2019-07-29
ES2910432T3 (es) 2022-05-12
JP2009535353A (ja) 2009-10-01
KR101514913B9 (en) 2022-06-24
KR20140132779A (ko) 2014-11-18
PL2679244T3 (pl) 2022-06-20
EP2676679B2 (en) 2024-08-28
CN105879021A (zh) 2016-08-24
SI2010219T1 (sl) 2015-12-31
BRPI0710918B8 (pt) 2021-05-25
EA201200929A1 (ru) 2013-05-30
PL2676679T3 (pl) 2019-06-28
CY1121251T1 (el) 2020-05-29
BR122020000285B1 (pt) 2023-05-09
ES2557504T3 (es) 2016-01-26
EP2010219A2 (en) 2009-01-07
CN101500612A (zh) 2009-08-05
JP2019194240A (ja) 2019-11-07
ES2885762T3 (es) 2021-12-15
MX359741B (es) 2018-10-09
EP2010219B1 (en) 2015-10-28
BRPI0710918A2 (pt) 2012-03-06
HK1196546A1 (zh) 2014-12-19
DK2010219T3 (en) 2016-01-11
TR201902402T4 (tr) 2019-03-21
CN105879021B (zh) 2020-11-24
PL2676679T5 (pl) 2024-11-12
EP2679245A3 (en) 2014-01-15
US20110172393A1 (en) 2011-07-14
JP6192115B2 (ja) 2017-09-06
CL2007001185A1 (es) 2008-01-18
JP2014221806A (ja) 2014-11-27
EP2679244B1 (en) 2022-03-23
EA200870480A1 (ru) 2009-04-28
CA2873346A1 (en) 2007-11-08
WO2007127665A2 (en) 2007-11-08
EP2676679B1 (en) 2019-01-02
TW200806315A (en) 2008-02-01
FR22C1027I1 (fr) 2022-09-09
LUC00267I2 (hu) 2025-04-25
KR20140004258A (ko) 2014-01-10
JP2014055169A (ja) 2014-03-27
EP2679245B1 (en) 2021-07-28
IL239978A0 (en) 2015-08-31
US8562999B2 (en) 2013-10-22
FR22C1027I2 (fr) 2024-10-11
KR20210111326A (ko) 2021-09-10
LTC2676679I2 (hu) 2025-04-10
SI2679245T1 (sl) 2021-11-30
KR101514847B1 (ko) 2015-04-24
HK1209358A1 (en) 2016-04-01
CN101500612B (zh) 2013-12-25
PL2679245T3 (pl) 2021-11-08
WO2007127665A3 (en) 2008-11-13
AU2007243019A1 (en) 2007-11-08
HUE028137T2 (hu) 2016-11-28
IL194753A (en) 2015-08-31
HRP20211417T1 (hr) 2021-12-10

Similar Documents

Publication Publication Date Title
HUS2200028I1 (hu) Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések
IL190885A0 (en) Immunogenic compositions and methods of use
ZA201203709B (en) Immunogenic compositions and methods
EP1988918A4 (en) ADJUVANZ AND VACCINE COMPOSITIONS
ZA200900347B (en) Preparation of pharmaceutical compositions
PT2101766T (pt) Composições e métodos de utilização de (r)-pramipexole
IL198513A0 (en) Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
IL197909A0 (en) Reduction of astringency in polyphenol compositions
PL2101766T3 (pl) Kompozycje i sposoby stosowania (R)-pramipeksolu
ZA200810162B (en) Phenylphrine pulsed release formulations and pharmaceutical compositions
ZA200900416B (en) Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives
ZA200908300B (en) Natural honey-containing compositions and method of preparation
EP2076281A4 (en) STABILIZING ALKYLGLYCOSIDIC COMPOSITIONS AND METHODS THEREOF
GB0401964D0 (en) Compositions for use as biocides and biostatics and uses of said compositions
ZA200806668B (en) Antiseptic compositions and methods of using same
IL192614A0 (en) Antiseptic compositions and methods of using same
AU2006906669A0 (en) Methods and Preparation and Uses of Xanthorrhoeaceae Compositions
AU2007906531A0 (en) Methods and Preparation and Uses of Xanthorrhoeaceae Compositions